Loading...
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme.
Khan, F Ottensmeier, C Popat, S Dua, D Dorey, N Ellis, S Szabo, M Upadhyay, S Califano, Raffaele Chan, S
Khan, F
Ottensmeier, C
Popat, S
Dua, D
Dorey, N
Ellis, S
Szabo, M
Upadhyay, S
Califano, Raffaele
Chan, S
Citations
Altmetric:
Abstract
Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.
Description
Date
2014-04-09
Publisher
Collections
Keywords
Type
Article
Citation
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. 2014: Eur J Cancer